Improving Hepatocellular Carcinoma Screening
Recruiting
N/A
Interventional Study
Magnetic Resonance Imaging
Hepatocellular Carcinoma
Screening
Contrast-enhanced US
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Screening
- Participants needed
- 330 (estimated)
- Sponsor
- Naik Vietti Violi · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a monocentric, single blind, interventional, single arm study. It is designed to compare the rates of detection of hepatocellular carcinoma (HCC) by ultrasound (US) used in clinical routine vs. abbreviated magnetic resonance imaging (AMRI). The hypothesis is that dynamic AMRI with extracellular contrast agent injection has a higher patient-level detection rate of HCC than screening US and …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* All adult patients with chronic liver disease and indication for HCC screening according to the European Association for the Study of the Liver recommendations.
* Informed Consent signed by the subject
Exclusion Criteria:
* History of HCC
* History of other malignancy
* Prio…
Contacts